Abstract
Background Although the rapid reperfusion by coronary artery bypass graft (CABG) surgery has significant success and it can cause decrease in mortality and morbidity rate, but this reperfusion paradoxically can cause ionic and metabolic damage that lead to myocardial damage and myocytes death. We examined whether perioperative exogenous erythropoietin (EPO) can reduce myocardial damage by reducing troponin I and creatine kinase (CKMB) level.
Highlights
Background the rapid reperfusion by coronary artery bypass graft (CABG) surgery has significant success and it can cause decrease in mortality and morbidity rate, but this reperfusion paradoxically can cause ionic and metabolic damage that lead to myocardial damage and myocytes death
We examined whether perioperative exogenous erythropoietin (EPO) can reduce myocardial damage by reducing troponin I and creatine kinase (CKMB) level
Patients in erythropoietin group were treated by common medical therapies and CABG plus 700 IU/kg erythropoietin (PD Poietin, puyeshdaroo, Iran), intravenously infusion, exactly 5 min after termination of cross clamp: at the start of reperfusion and patients in control group were treated by common medical therapies and CABG surgery plus 10 cc normal saline as placebo
Summary
Erythropoietin protection effects against ischemia-reperfusion injuries during coronary artery bypass graft surgery: a randomized, double blinded, placebo control study. From 23rd World Congress of the World Society of Cardio-Thoracic Surgeons Split, Croatia. From 23rd World Congress of the World Society of Cardio-Thoracic Surgeons Split, Croatia. 12-15 September 2013
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
